S-1: Avalon GloboCare Files for Resale of Common Stock

Avalon GloboCare Corp. has filed a registration statement for the resale of up to 19,436,278 shares of its common stock by selling stockholders.

Summary

• Avalon GloboCare Corp. has filed a registration statement (Form S-1) for the resale of up to 19,436,278 shares of its common stock by certain selling stockholders.
• The shares being offered for resale consist of common shares, shares issuable upon exercise of pre-funded warrants, Series A-1 warrants, Series A-2 warrants, and placement agent warrants.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders, except for potential proceeds from the exercise of warrants.
• The company is a technology-focused company developing consumer health and AI products, including the Keto Air breathalyzer and an AI-driven video generation platform.
• The company has a history of net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• The company is seeking additional capital to fund its operations and growth.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant increase in net losses, dwindling cash reserves, and the auditor's substantial doubt about the company's going concern status, despite strategic pivots.

Positives

• The company is actively developing and commercializing products in the consumer health and AI sectors.
• The AI platform, Catch-Up, is in beta testing with plans for a Phase 2 launch in Q3 2026, expanding its addressable market.
• The Keto Air breathalyzer is FDA registered and has a straightforward commercial pathway in North America.
• The company has a strategic focus on acquiring complementary AI businesses to generate near-term revenue.

Negatives

• The company has a history of net losses and an accumulated deficit, with substantial doubt about its ability to continue as a going concern.
• The company has limited operating history in its current business segments, making future prospects difficult to evaluate.
• The company expects its operating costs to increase significantly and has a limited cash balance that may not cover operating expenses for the next twelve months.
• The company faces intense competition in both its business segments, with many competitors having substantially greater resources.
• The company's common stock price has been and may continue to be highly volatile.
• The company has outstanding indebtedness that could adversely affect its financial condition and liquidity.

Risks

• The company has a limited operating history, making it difficult to evaluate its business and future prospects.
• The company has a history of net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• The company may not be successful in commercializing its AI platform or Keto Air product.
• The company faces intense competition in both business segments, with many competitors having substantially greater resources.
• The company's business is subject to rapid technological change, and failure to adapt could negatively impact its operations.
• The use of AI in the company's platform may give rise to legal liability, reputational harm, and regulatory scrutiny.
• The company's Catch-Up platform's AI avatar feature replicates individual voices and likenesses, exposing it to significant legal risks under right of publicity and biometric privacy laws.
• The content generated by the platform may infringe the intellectual property rights of third parties.
• Laws and regulations governing artificial intelligence are rapidly evolving, and compliance may be costly and uncertain.
• The company's platform's content may be restricted or removed by major social media and content distribution platforms.
• The company's business depends on the reliable performance of third-party cloud and infrastructure providers.
• Cybersecurity breaches or incidents could damage the company's reputation and adversely affect its business.
• The company is subject to data privacy and security laws that impose significant compliance obligations.
• The company will need to raise additional capital to fund its operations and growth, and may not be able to do so on acceptable terms.
• Future sales and issuances of the company's securities could result in additional dilution of stockholders' ownership.
• The company must maintain compliance with Nasdaq continued listing standards.
• Significant related party transactions, including the sale of its Route 9 property to a director, create conflicts of interest.
• The company's common stock price has been and may continue to be highly volatile.
• Adverse economic conditions could reduce demand for its products and services.
• Geopolitical developments and trade restrictions could adversely affect its operations.

Future Outlook

The company anticipates that it will take approximately one year from the date of the prospectus for the Catch-Up platform to begin generating meaningful revenue. The company is also actively seeking complementary AI acquisitions to supplement its current operations.

Industry Context

StockSavvy.ai notes that Avalon GloboCare is navigating a challenging market characterized by rapid technological advancements in AI and a competitive consumer health sector. The company's pivot towards AI, while potentially lucrative, carries significant execution risks and requires substantial capital investment.

Corporate Governance

Legal Proceedings

• On October 28, 2019, Research Institute at Nationwide Childrens Hospital filed a complaint against Dr. Zhou, Li Chen, Avalon GloboCare Corp., and Genexosome Technologies Inc. alleging misappropriation of trade secrets and violation of Ohio Uniform Trade Secrets Act. A settlement agreement was reached on June 7, 2022, involving payments and profit-sharing, with $363,450 accrued for litigation settlement as of December 31, 2025.

Related Party Transactions

• Wenzhao Lu, Chairman of the Board, sold 100% of the membership interests of Avalon RT 9 Properties, LLC to the Company for approximately $9,000,000 on February 18, 2026.
• Wenzhao Lu exchanged 9,000 shares of Series A Preferred Stock for 5,000 shares of Series D Preferred Stock on January 9, 2025.
• Wilbert Tauzin, a former director, and his son provided consulting services, with expenses of $60,794 recognized in 2025.
• The company has a line of credit agreement with Wenzhao Lu, which matured on December 31, 2024.

Stakeholder Impact

• Shareholders may experience dilution due to future equity issuances and potential conversion of preferred stock and warrants.
• The company's volatile stock price could lead to substantial losses for investors.
• The company's ability to continue as a going concern raises concerns for all stakeholders.
• The company's reliance on future financing could impact its operational stability and growth prospects.

Next Steps

• The company intends to seek stockholder approval for the conversion of Series E Preferred Stock at its 2026 annual meeting.
• The company is actively seeking complementary bolt-on AI acquisitions.

Key Dates

Recommendation

The company's financial condition, characterized by increasing losses, dwindling cash, and a going concern warning from auditors, coupled with significant operational and market risks, suggests a high probability of continued underperformance. The proposed resale of shares by existing stockholders, while providing liquidity for them, does not fundamentally improve the company's financial health or operational outlook in the near term.

Keywords

Avalon GloboCare Corp., Form S-1, Registration Statement, Common Stock, Resale, Warrants, AI Platform, Keto Air, Consumer Health, Financing, Startup, Technology